HRT Financial’s Galectin Therapeutics GALT Stock Holding History

HRT Financial’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-51,058	Closed	-$142K	–	4617
2026 Q1	$142K	Buy	+51,058	New	+$155K	﹤0.01%	3280
2025 Q3	–	Sell	-77,200	Closed	-$162K	–	3132
2025 Q2	$162K	Buy	+77,200	New	+$115K	﹤0.01%	2118
2025 Q1	–	Sell	-19,543	Closed	-$25K	–	2806
2024 Q4	$25K	Buy	+19,543	New	+$46.8K	﹤0.01%	2180
2022 Q3	–	Sell	-14,817	Closed	-$19K	–	3045
2022 Q2	$19K	Buy	+14,817	New	+$21.3K	﹤0.01%	2612
2021 Q4	–	Sell	-80,216	Closed	-$311K	–	3490
2021 Q3	$311K	Sell	80,216 -24,730	-24%	-$83.8K	﹤0.01%	2382
2021 Q2	$335K	Buy	+104,946	New	+$373K	﹤0.01%	2078
2018 Q4	–	Sell	-15,050	Closed	-$90K	–	647
2018 Q3	$90K	Buy	+15,050	New	+$82.8K	0.01%	366

Other funds holding GALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

HRT Financial's GALT Position: Q2 2026 in Review

HRT Financial sold out of Galectin Therapeutics (GALT) in Q2 2026, closing a stake of 51,058 shares — an estimated $142K sold.

HRT Financial first reported a position in GALT in Q3 2018 and held it in 7 quarters. The position peaked at $335K in Q2 2021. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

HRT Financial reported no remaining Galectin Therapeutics position as of Q2 2026 after selling out during the quarter.
HRT Financial sold 51,058 Galectin Therapeutics shares in Q2 2026, an estimated $142K.
HRT Financial first reported a position in Galectin Therapeutics in Q3 2018 and held it in 7 quarters.
HRT Financial's Galectin Therapeutics position peaked at $335K in Q2 2021.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.